Red cell membrane coated dihydromyricetin nanoparticles as well as preparation method and application thereof
By encapsulating dihydromycete nanoparticles in the red blood cell membrane using PLGA and polymer nonionic surfactant, the problems of low encapsulation rate and high biotoxicity were solved, and efficient drug encapsulation and biocompatibility were achieved. It significantly improved the therapeutic effect of myocardial oxidative injury.
Patent Information
- Application Number
- CN202410978071.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-12
AI Technical Summary
In the prior art, the encapsulation rate of dihydromycete nanoparticles wrapped in red blood cell membrane is too low, has high biotoxicity and low targeting, making it difficult to effectively treat myocardial oxidative damage.
Dihydrobamate nanoparticles are encapsulated in the red blood cell membrane by PLGA and polymer nonionic surfactants such as poloxamer 188 and acetone. The encapsulation rate is improved through stirring and extrusion technology, and the low-permeability centrifugation is optimized. and sonication parameters, efficient red blood cell membrane-encapsulated dihydrobamate nanoparticles were prepared.
It significantly improves the drug's loading effect and biocompatibility, enhances the drug effect, can effectively reduce myocardial oxidation damage, and improves the bioavailability and pharmacological effect of dihydromycein.
Smart Images

Figure CN118924696A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of dihydromyricetin nanoparticles, and particularly relates to red blood cell membrane-wrapped dihydromyricetin nanoparticles and a preparation method and application thereof. Background Art
[0002] Myocardial oxidative damage plays a vital role in cardiovascular diseases, and it is one of the important factors leading to the development of cardiovascular diseases. Myocardial oxidative damage refers to the situation in which myocardial cells are damaged by oxidative stress. Oxidative stress is a state caused by the imbalance of free radicals and antioxidant systems in the body, which can lead to oxidative damage to biological molecules such as cell membranes, proteins and nucleic acids. Superoxide dismutase (SOD) and malondialdehyde (MDA) are two key indicators for evaluating the process of myocardial oxidative damage. When myocardial cells are damaged, the intracellular MDA level increases, the SOD level decreases, and the ability of myocardial cells to scavenge oxygen free radicals weakens. Therefore, it is of great significance to reduce myocardial oxidative damage by inhibiting cellular oxidative stress. Dihydromyricetin (DMY) is extracted from the woody vine of the genus Aglaonema in the grape family, with a molecular formula of C 15 H 12 O8, with a molecular weight of 320, is a polyphenol compound. DMY has a significant antioxidant effect. As a natural antioxidant, it can remove free radicals in the body and reduce the damage of oxidative stress to cells. It is a very potential drug for the treatment of myocardial oxidative damage.
[0003] However, DMY has limited solubility and a significant first-pass effect in the gastrointestinal tract. Less absorption through the gastrointestinal tract results in low bioavailability, which, to a certain extent, restricts its clinical application. It is urgent to develop new drug delivery systems to improve the bioavailability of DMY. Nanotechnology is widely used in the research of drug preparations, which effectively promotes the development of new preparations by integrating carriers and drugs through preparation methods.
[0004] The Chinese patent application with publication number CN117503929A discloses erythrocyte membrane-wrapped PLGA-purpurin imide nanoparticles and a preparation method thereof, wherein PLGA is first dissolved in a solvent, then fully mixed with purpurin imide, stirred until the solvent evaporates, and a nanoparticle colloidal solution is obtained, and PLGA-purpurin imide nanoparticles are obtained after freeze-drying; the invention also adopts a hypotonic membrane rupture method to prepare erythrocyte membranes, and after ultrasonic treatment, an erythrocyte membrane vesicle solution is obtained, which is then mixed with PLGA-purpurin imide nanoparticles and extruded to obtain erythrocyte membrane-wrapped PLGA-purpurin imide nanoparticles. The purpurin imide drug selected in the patent has poor water solubility, and dimethyl sulfoxide needs to be used to dissolve the nanoparticles, which has certain cytotoxicity. The nanoparticle encapsulation efficiency in the patent is 33.08%, and the drug encapsulation effect needs to be improved.
[0005] The Chinese patent application with publication number CN111317714A involves the preparation of a natural active substance dihydromyricetin nanoemulsion. The dihydromyricetin nanoemulsion is prepared by a one-step emulsification method. ODO, Tween 80, PGPR, and dihydromyricetin are stirred and mixed at 30°C to form an oil phase. At the same time, water and glycerol are mixed at the same temperature to form an aqueous phase. The aqueous phase is added to the oil phase and stirred with a magnetic stirrer for 15 minutes to prepare a nanoemulsion with an average particle size of 100 nm. If the emulsion prepared by the patent is applied to biomimetic nanoparticles, the surfactants Tween 80 and PGPR may reduce the biocompatibility of the nanoparticles, and water and glycerol are not easy to volatilize and remain in the drug.
[0006] If the above two patents are combined to prepare bionic nanoparticles of dihydromyricetin encapsulated by red blood cell membranes, there will be technical problems such as too low encapsulation rate, high biological toxicity, and low targeting. Summary of the invention
[0007] In order to solve the above technical problems, the present invention provides a red blood cell membrane-encapsulated dihydromyricetin nanoparticle and a preparation method thereof, so as to improve the encapsulation rate and targeting of the prepared red blood cell membrane-encapsulated dihydromyricetin nanoparticle.
[0008] The present invention also provides the use of erythrocyte membrane-wrapped dihydromyricetin nanoparticles in the preparation of a medicine for treating myocardial oxidative damage.
[0009] The technical solution adopted by the present invention to solve its technical problem is:
[0010] A method for preparing red blood cell membrane-encapsulated dihydromyricetin nanoparticles comprises the following steps:
[0011] S1. Preparation of dihydromyricetin nanoparticles: dissolving dihydromyricetin and PLGA in an organic solvent as an organic phase, dissolving a high molecular nonionic surfactant in water and stirring evenly as an aqueous phase, injecting the organic phase into the aqueous phase, stirring and dispersing evenly to obtain dihydromyricetin nanoparticles;
[0012] The organic solvent is one or two of acetone, methanol and acetonitrile;
[0013] The polymer nonionic surfactant is one or two of poloxamer 188, Tween 80, and polyethylene glycol;
[0014] S2. Mixing the erythrocyte membrane and the dihydromyricetin nanoparticles prepared in S1 at a volume ratio of 1:(3-5), stirring, and extruding to obtain erythrocyte membrane-coated dihydromyricetin nanoparticles.
[0015] The present invention improves the encapsulation rate of dihydromyricetin nanoparticles wrapped in red blood cell membranes by adding PLGA (polylactic acid-glycolic acid copolymer), organic solvents (acetone, etc.), and high molecular non-ionic surfactants (poloxamers, etc.), thereby improving the drug encapsulation effect, improving biocompatibility, and having higher stability and stronger pharmacodynamic effects.
[0016] The role of the red blood cell membrane and the dihydromyricetin nanoparticles prepared in S1 in a volume ratio of 1: (3-5) is to ensure that the dihydromyricetin nanoparticles are wrapped with a minimum of red blood cell membrane, saving materials; in addition, if the amount of red blood cell membrane used is too large, the nanoparticles will stick together.
[0017] In one preferred embodiment, the extraction of red blood cell membrane includes the following steps: collecting whole blood of SD rats and centrifuging to remove upper white blood cells and plasma, washing and centrifuging, hypotonic treatment of red blood cells for 0.5-1.5 hours, then absorbing water and bursting, removing hemoglobin after centrifugation, washing the lower red blood cell membrane, ultrasonicating for 20-40 minutes, and squeezing out to obtain evenly dispersed red blood cell membrane liposomes.
[0018] Preferably, the erythrocyte hypotonic treatment is performed for 0.5-1 h and the ultrasound is performed for 20-30 min. The above parameter range can improve the encapsulation efficiency and drug loading of the erythrocyte membrane-wrapped dihydromyricetin nanoparticles.
[0019] In one preferred embodiment, the hypotonic treatment medium used in the extraction of red blood cell membranes is (0.25-0.4)×PBS.
[0020] 0.25xPBS is 0.25 times PBS, which is diluted by adding three times the volume of water.
[0021] In one preferred embodiment, the mass ratio of dihydromyricetin, PLGA, and high molecular non-ionic surfactant in S1 is 3-5:15-25:25-35, and the mass concentration of dihydromyricetin in S1 is 3-5 mg / mL.
[0022] In one preferred embodiment, the volume ratio of the organic solvent to water in S1 is 1-3:5-15.
[0023] In one preferred embodiment, the mass volume ratio of dihydromyricetin to organic solvent in S1 is 3-5 mg:1-3 mL.
[0024] In one preferred embodiment, the stirring parameter in S2 is 600-1200 rpm, and the stirring time in S2 is 1-3 h.
[0025] In one preferred embodiment, in the step of extracting the red blood cell membrane, the red blood cell membrane is uniformly dispersed by extruding it through a liposome extruder 1-3 times through a 200-400 nm PC membrane.
[0026] Preferably, in the step of extracting the red blood cell membrane, the centrifugal speed is 2000-4000 rpm, the centrifugal time is 5-15 min, and the temperature is 3-5°C.
[0027] Preferably, PBS is used for washing in the step of extracting the red blood cell membrane.
[0028] Preferably, in the step of extracting the red blood cell membrane, the speed of centrifugation after washing is 12000-14000 rpm, the time of centrifugation after washing is 5-15 min, and the temperature is 3-5°C.
[0029] Preferably, in the step of extracting the red blood cell membrane, the red blood cell membrane is uniformly dispersed by extruding it through a liposome extruder 1-3 times through a 200-400 nm PC membrane.
[0030] Preferably, after the stirring in S2 is completed, the liposome is repeatedly extruded 20-40 times through a 200-400 nm PC membrane using a liposome extruder to obtain the erythrocyte membrane-wrapped dihydromyricetin nanoparticles.
[0031] Preferably, the aqueous phase in S1 is stirred at 500-700 rpm for 1-2 h.
[0032] Preferably, in S1, the organic phase is injected into the aqueous phase and the stirring time is 1-2 h.
[0033] Preferably, in S1, a cell ultrasonic disruptor is used for dispersion, and the dispersion time is 5-15 minutes.
[0034] Preferably, the PC membrane of the liposome extruder used in S2 is 200-400 nm, and the number of extrusions is 20-40 times.
[0035] The invention also discloses erythrocyte membrane-wrapped dihydromyricetin nanoparticles prepared according to the preparation method of erythrocyte membrane-wrapped dihydromyricetin nanoparticles.
[0036] The invention also discloses the use of erythrocyte membrane-wrapped dihydromyricetin nanoparticles prepared according to the preparation method in preparing a drug for treating myocardial oxidative damage.
[0037] The present invention also provides an application of the dihydromyricetin bionic nanoparticles wrapped by erythrocyte membranes in treating myocardial oxidative damage.
[0038] Compared with the Chinese patent application with publication number CN117503929A, the present application only uses organic solvent acetone to dissolve the drug dihydromyricetin and volatilizes it by stirring to ensure the safety of the nanoparticles, and a cytotoxicity experiment is performed to judge the biocompatibility of the nanoparticles. Secondly, the present application optimizes the preparation process to achieve a nanoparticle encapsulation rate of 80.9%, thereby improving the drug encapsulation effect.
[0039] Compared with the Chinese patent application with publication number CN111317714A, the present application adopts PLGA and poloxamer as carriers to encapsulate and protect drugs and improve the stability of drugs. PLGA and poloxamer are biodegradable polymer materials with non-toxic and harmless characteristics, excellent emulsification and stabilization capabilities, and can form a relatively stable nanostructure, which is an excellent drug carrier. Poloxamer, as a non-ionic surfactant, has a unique hydrophilic-hydrophobic structure, which can improve the solubility of drugs and promote absorption. It can also stabilize the nanoparticles modified by erythrocyte membranes, prevent the denaturation and shedding of membrane proteins, and ensure that the nanoparticles have good biocompatibility and stability in vivo. The present application selects PLGA as a carrier to prepare dihydromyricetin nanoparticles, and then encapsulates the erythrocyte membrane to construct biomimetic nanoparticles, which improves the bioavailability of the drug dihydromyricetin and prepares nanoparticles with better biocompatibility, higher stability, and stronger pharmacodynamics.
[0040] The object of the present invention, dihydromyricetin, is a polyphenol compound extracted from a woody vine of the genus Ampelopsis of the grape family, and has significant pharmacological effects such as anti-oxidation, anti-inflammatory, antibacterial, anti-tumor, liver protection and cardiovascular system protection, and is widely used in the treatment of cardiovascular diseases such as arrhythmia, hypertension, acute myocardial infarction, myocardial hypertrophy and ventricular hypertrophy. However, its solubility is limited, and it is easily cleared by the immune system after entering the body. The existing technology is mostly limited to exploring its efficacy and mechanism of action in treating myocardial oxidative damage, and there has been no research report on making it into a new dosage form of bionic nanoparticles modified with erythrocyte membranes.
[0041] In addition to increasing biocompatibility and low immunogenicity, the present application uses red blood cell membrane wrapping to improve the bioavailability and pharmacological effect of the drug dihydromyricetin. The comparative experiments are specifically reflected in: Figure 4 Compared with the raw material drug dihydromyricetin, the bionic nanoparticles have a sustained release effect; Figure 7 Compared with DMY and DMY@NPs, R@DMY@NPs has a stronger improvement effect on myocardial cell injury; Fig. 9 By setting up the raw material dihydromyricetin group for comparison, it was found that the prepared bionic nanoparticles can reduce the phagocytosis of RAW264.7 cells and enhance the uptake of H9c2 cells.
[0042] The present invention innovates the hypotonic treatment time and ultrasonic time of the hypotonic centrifugation method, and the extracted erythrocyte membrane is suitable for preparing erythrocyte membrane-wrapped dihydromyricetin bionic nanoparticles. The dihydromyricetin nanoparticles are prepared by the emulsified solvent volatilization method, and then the erythrocyte membrane-wrapped dihydromyricetin bionic nanoparticles R@DMY@NPs are synthesized by using a liposome extruder. The preparation process of the nanoparticles is optimized and evaluated by the response surface method, and then the H9c2 cardiomyocyte oxidative damage model is constructed to evaluate the therapeutic effect of the bionic nanoparticles. The experimental results show that the bionic nanoparticles have stable performance, good biocompatibility, can improve the bioavailability of dihydromyricetin, can significantly alleviate cardiomyocyte oxidative damage, and are a new potential preparation for treating myocardial oxidative damage.
[0043] In this application, PLGA was used as a carrier to prepare bionic nanoparticles. The optimal preparation process was selected by examining process parameters such as carrier and drug dosage, red blood cell membrane extraction, stirring speed and time, and cell experiments were conducted to evaluate the biocompatibility, targeting and pharmacodynamics of the bionic nanoparticles.
[0044] The beneficial effects of the present invention are:
[0045] (1) The present invention extracts erythrocyte membranes and synthesizes erythrocyte membrane-wrapped dihydromyricetin biomimetic nanoparticles R@DMY@NPs for the first time. R@DMY@NPs can significantly reduce oxidative damage in H9c2 cardiomyocytes, reduce intracellular LDH and MDA levels, and increase SOD levels, with a more significant therapeutic effect than DMY; the R@DMY@NPs prepared by the present invention have good biocompatibility and targeting, can reduce the phagocytic clearance of RAW264.7 cells, and enhance the uptake function of H9c2 cells.
[0046] (2) The present invention found that R@DMY@NPs have regular shapes, stable properties, and good in vitro sustained release effects.
[0047] (3) The erythrocyte membrane-encapsulated dihydromyricetin biomimetic nanoparticles prepared by the present invention provide new ideas and solutions for the development of new dosage forms of dihydromyricetin and the treatment of myocardial oxidative damage. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 It is a schematic diagram of the preparation process of the present invention.
[0049] Figure 2 3D diagram and contour map of the R@DMY@NPs preparation process optimized by response surface methodology.
[0050] Figure 3 A is the characterization diagram of R@DMY@NPs, A is the particle size diagram of R@DMY@NPs, B is the potential diagram of R@DMY@NPs, and C is the transmission electron microscope diagram of R@DMY@NPs.
[0051] Figure 4 This is the in vitro drug release curve of R@DMY@NPs (n=3).
[0052] Figure 5 These are the results of the stability investigation of R@DMY@NPs, A is the change in particle size of R@DMY@NPs within 15 days, B is the change in PDI of R@DMY@NPs within 15 days, and C is the change in absorbance of R@DMY@NPs in serum within 5 hours (n=3).
[0053] Figure 6 In vitro toxicity test results of different concentrations of NPs, DMY, DMY@NPs, and R@DMY@NPs on H9c2 cells and RAW264.7, n=6.
[0054] Figure 7 The improvement effects of NPs, DMY, DMY@NPs and R@DMY@NPs on H9c2 cell damage at different administration times (compared with the model group, *P<0.05, **P<0.01, ***P<0.001, n=6).
[0055] Figure 8 Effects of NPs, DMY, DMY@NPs and R@DMY@NPs on the changes in LDH, MDA and SOD contents in H9c2 cells (compared with the normal group, *P<0.05, **P<0.01, ***P<0.001, n=6).
[0056] Fig. 9 These are the results of in vitro anti-phagocytosis and cellular uptake. A is the fluorescence image of RAW264.7 cells' anti-phagocytosis of DMY@NPs and R@DMY@NPs in vitro, and B is the fluorescence image of H9c2 cells' uptake of DMY@NPs and R@DMY@NPs. DETAILED DESCRIPTION
[0057] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Without departing from the spirit and essence of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention are within the scope of the present invention. The consumables and instruments used in the following examples can all be obtained commercially, and the methods used in the examples are consistent with conventional methods unless otherwise specified.
[0058] Example 1
[0059] Preparation of biomimetic nanoparticles
[0060] Four SPF male SD rats, weighing 250-300 g, were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd. and housed in the Animal Experiment Center of Hunan University of Chinese Medicine at a temperature of 25±2°C, a humidity of 50-55%, and 12h light-dark cycles. They were allowed to eat and drink freely. The animal ethics committee of Hunan University of Chinese Medicine reviewed the compliance with the standards, with the ethics approval number: LLBH-202212060002. After one week of adaptive feeding, rats were anesthetized with 2% sodium pentobarbital, and whole blood was collected in anticoagulant tubes using the abdominal aorta method. The blood was centrifuged at 3000 rpm for 15 min at 4°C to remove the upper plasma and leukocytes. The lower layer was washed with PBS and centrifuged at 3000 rpm for 5 min. The upper layer was discarded, and the washed red blood cells were placed in 20 times the volume of 0.25×PBS and treated with hypotonic treatment on ice for 1 h to allow the red blood cells to absorb water and burst. The blood was centrifuged at 12000 rpm in a 4°C centrifuge for 15 min, and the upper hemoglobin layer was discarded. The lower red blood cell membrane was washed with 0.25×PBS and centrifuged until the supernatant was colorless. The blood was sonicated for 30 min and squeezed through 400 and 200 nm polycarbonate (PC) membranes in sequence using a liposome extruder. The blood was resuspended in PBS to obtain uniformly dispersed red blood cell membrane RBCM.
[0061] Accurately weigh 4 mg of DMY and 20 mg of PLGA and dissolve them in 1 mL of acetone as the organic phase, weigh 30 mg of poloxamer and dissolve them in 10 mL of water as the aqueous phase. Place the aqueous phase in a magnetic stirrer at 600 rpm, slowly inject the organic phase, stir at room temperature for 1.5 h, and then ultrasonicate in an ultrasonic cell crusher for 10 min to obtain DMY@NPs.
[0062] DMY@NPs and RBCM were mixed at a volume ratio of 4:1 in a magnetic stirrer at 640 rpm and stirred at room temperature for 2 h. The mixture was repeatedly extruded through a 200 nm liposome extruder to obtain the R@DMY@NPs.
[0063] Take 2mL of L@DMY@NPs sample solution in a cuvette and a potential sample cell, and measure the sample particle size, dispersion index (PDI) and Zeta potential in a Malvern laser particle size analyzer. Take 1mL of L@DMY@NPs, add acetonitrile to ultrasonically demulsify for 30 minutes, centrifuge at 12000rpm for 10 minutes, and then use HPLC to determine the DMY content. Chromatographic conditions: Chromatographic column: Hyperdil BDSC 18 Column (4.6mm×200mm, 5μm); mobile phase: 0.1% phosphoric acid aqueous solution-methanol (75:25); flow rate: 1.0mL / min detection wavelength: 290nm; column temperature: 40℃; injection volume: 10μL. Another 1mL of R@DMY@NPs was freeze-dried and weighed, and the DMY content was determined after adding acetonitrile for re-dissolution. The encapsulation efficiency and drug loading were calculated according to the following formula:
[0064] Encapsulation efficiency = W 纳米粒中DMY / W 投药量 ×100%
[0065] Drug loading = W 纳米粒中DMY / W 纳米粒 ×100%
[0066] Examples 2-3 and Comparative Examples 1-2
[0067] Examples 2-3 and Comparative Examples 1-2 respectively provide a preparation method for dihydromyricetin bionic nanoparticles encapsulated by erythrocyte membranes. Compared with Example 1, the effect of hypotonic time on the particle size, PDI, encapsulation efficiency and drug loading of bionic nanoparticles was analyzed and investigated.
[0068] Table 1 Hypotonic time used in Examples 2-3 and Comparative Examples 1-2
[0069] Example / Comparative Example Hypotonic time / h Example 2 0.5 Example 3 1.5 Comparative Example 1 0 Comparative Example 2 2
[0070] The particle size, PDI, encapsulation efficiency and drug loading of the erythrocyte membrane-encapsulated dihydromyricetin biomimetic nanoparticles prepared in Example 2-3 and Comparative Example 1-2 were measured, and the results were as follows:
[0071] Table 2 Results of Examples 2-3 and Comparative Examples 1-2
[0072] Example / Comparative Example Particle size / nm PDI Encapsulation rate / % Approximate load / % Example 2 208.3 0.312 74.1 7.7 Example 3 226.7 0.277 65.3 5.6 Comparative Example 1 432.8 0.431 54.4 4.3 Comparative Example 2 279.9 0.308 61.4 4.8
[0073] From the results in Table 2, it can be seen that as the hypotonic treatment time increases, the particle size and PDI of the biomimetic nanoparticles gradually decrease. This is because the hypotonic treatment allows the red blood cell membrane to fully rupture and can be wrapped on the surface of the dihydromyricetin nanoparticles to form stable nanoparticles. When the hypotonic treatment time is 1h, the particle size and PDI are the smallest, and the encapsulation rate and drug loading are the best.
[0074] Examples 4-5 and Comparative Examples 3-4
[0075] Examples 4-5 and Comparative Examples 3-4 respectively provide a preparation method for dihydromyricetin bionic nanoparticles encapsulated by erythrocyte membranes. Compared with Example 1, the effect of ultrasound time on the particle size, PDI, encapsulation efficiency and drug loading of bionic nanoparticles was analyzed and investigated.
[0076] Table 3 Ultrasonic time of Examples 4-5 and Comparative Examples 3-4
[0077] Example / Comparative Example Ultrasonic time / min Example 4 20 Example 5 40 Comparative Example 3 10 Comparative Example 4 50
[0078] The particle size, PDI, encapsulation efficiency and drug loading of the erythrocyte membrane-encapsulated dihydromyricetin biomimetic nanoparticles prepared in Examples 4-5 and Comparative Examples 3-4 were measured, and the results were as follows:
[0079] Table 4 Results of Examples 4-5 and Comparative Examples 3-4
[0080] Example / Comparative Example Particle size / nm PDI Encapsulation rate / % Drug loading / % Example 4 208.3 0.279 69.6 8.9 Example 5 213.8 0.286 59.4 8.2 Comparative Example 3 313.4 0.332 43.4 5.8 Comparative Example 4 247.5 0.298 44.9 7.1
[0081] From the results in Table 4, it can be seen that as the ultrasonic time increases, the particle size and PDI of the bionic nanoparticles gradually decrease and then show an increasing trend. Taking comprehensive consideration, the particle size, PDI, encapsulation efficiency and drug loading of the bionic nanoparticles are most suitable when the ultrasonic time is 30 minutes.
[0082] Example 6
[0083] Example 6 investigated the effect of 0.25-0.4×PBS hypotonic solution on erythrocyte membrane extraction.
[0084] The results showed that when 0.25×PBS was used as the hypotonic solution, the erythrocyte membrane had normal morphology, while other hypotonic solutions would produce hemolytic effect on the erythrocyte membrane.
[0085] Example 7
[0086] Example 7 investigated the effect of the mass ratio of dihydromyricetin, PLGA, and high molecular weight nonionic surfactant (3-5:20-25:25-35) on the particle size, PDI, encapsulation efficiency, and drug loading rate of nanoparticles. The prepared nanoparticles were measured, and the results were as follows:
[0087] Table 5 Results of Example 7
[0088] Example 7 Particle size / nm PDI Encapsulation rate / % Drug loading rate / % Dihydromyricetin 3mg 364.3 0.298 43.2 7.2 Dihydromyricetin 4mg 279.8 0.276 56.8 8.9 Dihydromyricetin 5mg 504.8 0.277 37.4 6.4 PLGA15mg 339.7 0.31 5 55.3 5.8 PLGA20mg 263.5 0.303 61.2 6.7 PLGA25mg 290.4 0.378 44.8 2.5 Poloxamer 25mg 317.9 0.365 50.2 3.3 Poloxamer 30mg 284.3 0.324 59.6 6.9 Poloxamer 35mg 389.0 0.393 27.9 3.8
[0089] The results showed that when the mass ratio of dihydromyricetin, PLGA and high molecular non-ionic surfactant was 4:20:30, the particle size and PDI of the nanoparticles were the smallest, and the encapsulation efficiency and drug loading were the best.
[0090] Example 8
[0091] Example 8 investigated the effect of the volume ratio of the organic phase to the aqueous phase (1-3:5-15) on the particle size, PDI, encapsulation efficiency and drug loading rate of the nanoparticles. The prepared nanoparticles were tested and the results were as follows:
[0092] Table 6 Results of Example 8
[0093] Example 8 Particle size / mm PDI Encapsulation rate / % Drug loading rate / % Organic phase 1 mL 198.6 0.265 74.9 9.8 Organic phase 2mL 278.4 0.277 68.3 8.2 Organic phase 3mL 294.3 0.304 49.0 4.3 Aqueous phase 5mL 369.4 0.274 58.4 5.5 Aqueous phase 10 mL 177.6 0.269 78.7 10.1 Aqueous phase 15mL 239.8 0.275 60.3 7.3
[0094] The results showed that when the volume ratio of organic phase to aqueous phase was 1:10, the particle size, PDI, encapsulation efficiency and drug loading of the nanoparticles were most suitable.
[0095] Example 9
[0096] Example 9 investigated the effect of the mass volume ratio of dihydromyricetin to the organic phase (3-5:1-3) on the particle size, PDI, encapsulation efficiency and drug loading rate of the nanoparticles. The prepared nanoparticles were measured and the results were as follows:
[0097] Table 7 Results of Example 9
[0098] Example 9 Particle size / nm PDI Encapsulation rate / % Drug loading rate / % Dihydromyricetin 3mg 207.3 0.314 54.5 8.3 Dihydromyricetin 4mg 169.8 0.275 79.8 10.4 Dihydromyricetin 5mg 297.4 0.463 36.7 3.7 Organic phase 1 mL 193.2 0.267 68.4 10.0 Organic phase 2mL 246.8 0.298 43.2 8.2 Organic phase 3mL 343.5 0.293 51.1 4.4
[0099] The results showed that when the mass volume ratio of dihydromyricetin to organic phase was 4:1, the particle size and PDI of the nanoparticles were the smallest, the encapsulation efficiency and drug loading were the largest, and the prepared nanoparticles were most suitable.
[0100] Example 10
[0101] Optimization of R@DMY@NPs preparation process by response surface methodology
[0102] The volume ratio of RBCM to DMY@NPs (A), magnetic stirring speed (B), and stirring time (C) were used as independent variables. The optimal level screened out in the previous single-factor experiment was referenced, and the optimal level and its two levels before and after were selected as the high (+1), medium (0), and low (-1) levels of the independent variables. The response surface design was carried out with encapsulation efficiency, drug loading, particle size, and PDI as indicators. All indicators were standardized to a normalized value of 0∽1, and the geometric mean was calculated to calculate the OD value. The Hassan method was used to perform digital transformation to obtain the normalized values dmax and dmin for factors with larger values (encapsulation efficiency, drug loading) and factors with smaller values (particle size, PDI). At the same time, the Design-Expert software was used for fitting verification and variance analysis. The calculation formula is as follows:
[0103] dmax=(Yi-Ymin) / (Ymax-Ymin)
[0104] dmin=(Ymax-Yi) / (Ymax-Ymin)
[0105] OD=(d1d2...d k ) 1 / k (k is the index number)
[0106] The results of 17 groups of experiments designed by Design Expert 13.0 software showed that the R@DMY@NPs prepared by the 14th group design had the smallest particle size, and the encapsulation efficiency and drug loading were high, as shown in Table 8. The regression equation obtained by analysis was:
[0107] 0D=0.3719-0.0249A+0.2274B+0.0763C+0.0950AB+0.1777AC-0.0042BC+0.1877A 2 -0.0061B2 -0.0342C 2 , R 2 =0.9498.
[0108] Table 8 Response surface experiment results
[0109]
[0110] The variance analysis results of this example are shown in Table 8. The response surface 3D graph and contour lines are shown in Table 8. Figure 2 As shown, the results show that the volume ratio of DMY@NPs to RBCM (A) and the magnetic stirring speed (B) have the most significant effects on the preparation of R@DMY@NPs (P < 0.05). The optimal preparation process of R@DMY@NPs was finally obtained by optimization: the volume ratio of DMY@NPs to RBCM was 4:1, the magnetic stirring speed was 640rpm, and the stirring time was 2h. R@DMY@NPs were prepared according to the preparation process optimized by the BBD experiment. The measured particle size was 167.4nm, the PDI was 0.257, the encapsulation efficiency was 80.9%, the drug loading was 11.2%, and the calculated OD value was 0.9314, which was slightly different from the model predicted OD value of 0.9457, indicating that the obtained preparation process was more reliable.
[0111] Table 9 Response surface variance analysis results
[0112]
[0113] Embodiment 11
[0114] R@DMY@NPs characterization and evaluation
[0115] R@DMY@NPs were added dropwise onto the copper mesh wrapped with carbon film, left to dry for 10 min, and then 2% phosphotungstic acid solution was added for negative staining for 5 min. The samples were observed under a transmission electron microscope and photographed.
[0116] The in vitro release of R@DMY@NPs was determined by dynamic dialysis. 5 mL of R@DMY@NPs, DMY@NPs and DMY API were accurately measured and placed in a pre-treated dialysis bag, placed in 200 mL of PBS dialysis medium containing 20% ethanol, and stirred at a constant speed of 100 rpm at room temperature. 1 mL of samples were taken at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 48, 60, and 72 h, and the same volume of dialysis medium was added after taking. The samples were filtered through a 0.22 μm membrane into the liquid phase to determine the DMY content and calculate the cumulative release rate of the drug.
[0117] Prepared R@DMY@NPs were stored at 4°C, and their particle size and PDI were measured at 0, 1, 3, 5, 10, and 15 days to investigate their storage stability within 15 days. R@DMY@NPs were mixed with 100% fetal bovine serum and incubated at 37°C for 4 hours. The absorbance values were measured at 570 nm on an ELISA reader at 0, 1, 2, 3, 4, and 5 hours to detect the aggregation of biomimetic nanoparticles in serum.
[0118] In this example, R@DMY@NPs are characterized as follows Figure 3 As shown in Figure 2, the in vitro drug release of R@DMY@NPs is shown in Figure 2. Figure 4 As shown in Figure 2, the stability results of R@DMY@NPs are as follows: Figure 5 shown.
[0119] Figure 3 The results showed that the particle size of R@DMY@NPs was 164.4nm, the potential was -19.2mV, and the PDI was 0.248. Transmission electron microscopy showed that R@DMY@NPs were regularly round or spherical in shape, with no adhesion distribution phenomenon, and a clear shell-core structure was visible, indicating that the outer layer of DMY@NPs was covered by the red blood cell membrane.
[0120] Figure 4 The results showed that the release of DMY API was basically balanced at 24 hours, and the final release rate was nearly 92%, indicating that the dialysis bag had no obvious adsorption effect on the drug, and the dynamic dialysis method used was feasible. The release of DMY@NPs no longer increased after 48 hours, and the release rate within 48 hours reached 75%, while R@DMY@NPs delayed release until 60 hours, and the release rate within 60 hours reached 67%. Therefore, compared with API and DMY@NPs, R@DMY@NPs has a sustained release effect.
[0121] Figure 5 The results showed that the particle size of R@DMY@NPs fluctuated within 164-170nm within 15 days, and the PDI was stable within 0.3, indicating that it has good stability at 4°C. By simulating the environment of R@DMY@NPs in the body and measuring the absorbance value, the results showed that the absorbance value of R@DMY@NPs in serum did not change significantly within 5 hours, indicating that R@DMY@NPs can resist the aggregation effect induced by serum and can exist stably in serum.
[0122] Example 12
[0123] Study on the protection of R@DMY@NPs against myocardial oxidative damage
[0124] The cytotoxicity experiment was designed to evaluate the in vitro safety of nanoparticles. Well-growing H9c2 cells and RAW264.7 cells were seeded into 96-well plates (1×10 4cells / well), each well containing 200 μL of cell suspension, cultured for 24 hours and then administered the drugs after the cells attached to the wall, and divided them into a control group, different concentrations of NPs, DMY, DMY@NPs, and R@DMY@NPs groups (12.5, 25, and 50 μg / mL), with 6 replicate wells in each group. After culturing in the incubator for 24 hours, 100 μL of culture medium containing 10% CCK-8 reagent was added, and after incubation in the incubator for 2 hours, the absorbance value was measured at 450 nm on a microplate reader and the cell survival rate was calculated.
[0125] Well-growing H9c2 cells were seeded into 96-well plates (1×10 4 The cells were cultured adherently for 24 h and then divided into a normal group, a model group, NPs, DMY, DMY@NPs, and low-, medium-, and high-dose R@DMY@NPs groups. Each group had 6 replicate wells. Except for the normal group, the other groups were added with 400 μM H2O2 for 4 h to establish a myocardial oxidative injury model. After modeling, the drugs were administered and the cells were placed in the incubator for 4, 8, 12, and 24 h, respectively. The culture medium containing 10% CCK-8 reagent was added and incubated for 2 h, and the absorbance was measured at 450 nm to evaluate the recovery degree of myocardial injury.
[0126] Normally growing cells were seeded into 96-well plates (1×10 4 / well) and divided them into control group, model group, NPs, DMY, DMY@NPs, and different concentrations of R@DMY@NPs groups. After adhesion, myocardial injury models were established and the drugs were given and incubated for 8 hours. Then LDH, SOD, and MDA kits were used to detect the contents of corresponding indicators.
[0127] In this example, the cytotoxicity results are as follows Figure 6 As shown in Figure 2, the improvement effect of R@DMY@NPs on H9c2 cell damage at different administration times is as follows Figure 7 As shown in Figure 2, the effects of R@DMY@NPs on the changes in LDH, MDA, and SOD contents in H9c2 cells are as follows: Figure 8 shown.
[0128] Figure 6 The results showed that with the increase of concentration, there was no significant difference in the absorbance values of NPs, DMY, DMY@NPs, and R@DMY@NPs, and the cell survival rate of each group was above 90%, indicating that each drug had no toxicity to H9c2 and RAW264.7 cells. The results of the NPs group showed that the nanomaterials had no effect on the survival of the two cells, indicating that the prepared nanoparticles had good biocompatibility.
[0129] Figure 7The results showed that different concentrations of DMY, DMY@NPs and R@DMY@NPs all had different degrees of improvement on myocardial damage caused by H2O2. The NPs group had no improvement or aggravation on cell damage. Compared with DMY and DMY@NPs, R@DMY@NPs had a stronger improvement on myocardial cell damage. After DMY@NPs were wrapped by the red blood cell membrane, the rejection reaction of the immune system was reduced, the stability and biocompatibility of DMY were improved, thereby increasing the residence time of DMY in the cells and enhancing the effect. In addition, by examining different administration times, it was found that when the administration was 8h, R@DMY@NPs could significantly improve the viability of H9c2 cells, with a cell survival rate of 80%, while when the administration time was prolonged, the cell survival rate decreased slightly. Therefore, the optimal administration time in the present invention is selected as 8h.
[0130] Figure 8 The results showed that when cells were damaged by oxidation, the intracellular LDH and MDA levels increased significantly, while the SOD content decreased. After incubation with drug administration, NPs had no significant effect on the changes in LDH, MDA, and SOD levels, while the DMY, DMY@NPs, and R@DMY@NPs groups could reduce the levels of LDH and MDA in damaged cells and increase the level of SOD. As the concentration of R@DMY@NPs increased, the cell antioxidant capacity was stronger, indicating that R@DMY@NPs could effectively reduce the oxidative damage of H9c2 cells.
[0131] Embodiment 13
[0132] Study on anti-phagocytosis and cellular uptake of R@DMY@NPs in vitro
[0133] Normally growing H9c2 cells and RAW264.7 cells were inoculated into 24-well plates, with 1 mL of cell suspension (5×10 4 After the cells adhered to the wall, DMY@NPs and R@DMY@NPs were given respectively, and 1 mL of FITC was added and mixed for 4 h. After the cells were washed with PBS, the position distribution of the nanoparticles and the cell staining were observed under an inverted fluorescence microscope.
[0134] The in vitro anti-phagocytic results of R@DMY@NPs are shown in Fig. 9 As shown in A, the cellular uptake results are Fig. 9 As shown in B.
[0135] Fig. 9 A The results show that the fluorescence intensity of the R@DMY@NPs group is lower than that of the DMY@NPs group, which indicates that the phagocytic effect of RAW264.7 cells on R@DMY@NPs is reduced. Coating DMY with red blood cell membrane for protection can reduce the clearance of the endothelial system and help prolong its circulation in the body. Fig. 9B shows that the fluorescence intensity of the R@DMY@NPs group is significantly stronger than that of DMY@NPs, indicating that H9c2 cells have a stronger uptake effect on R@DMY@NPs and a higher affinity, achieving precise delivery of R@DMY@NPs. The comprehensive results show that R@DMY@NPs have good anti-phagocytic ability and cell targeting function.
[0136] A person skilled in the art should understand that the discussion of any of the above embodiments is merely illustrative and is not intended to imply that the scope of protection of the present application is limited to these examples. In line with the concept of the present application, the technical features in the above embodiments or different embodiments may be combined, the steps may be implemented in any order, and there are many other variations of different aspects of one or more embodiments of the present application as described above, which are not provided in detail for the sake of simplicity.
[0137] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A method for preparing red blood cell membrane-encapsulated dihydromyricetin nanoparticles, Features The following steps are involved: S1. Preparation of dihydromyricetin nanoparticles: dissolving dihydromyricetin and PLGA in an organic solvent as an organic phase, dissolving a high molecular nonionic surfactant in water and stirring evenly as an aqueous phase, injecting the organic phase into the aqueous phase, stirring and dispersing evenly to obtain dihydromyricetin nanoparticles; The organic solvent is one or two of acetone, methanol and acetonitrile; The polymer nonionic surfactant is one or two of poloxamer 188, Tween 80, and polyethylene glycol; S2. Mixing the erythrocyte membrane and the dihydromyricetin nanoparticles prepared in S1 at a volume ratio of 1:(3-5), stirring, and extruding to obtain erythrocyte membrane-coated dihydromyricetin nanoparticles.
2. The preparation method according to claim 1, It is characterized in that The extraction of red blood cell membrane in S2 includes the following steps: collecting whole blood of SD rats and centrifuging to remove upper white blood cells and plasma, washing and centrifuging, subjecting red blood cells to hypotonic treatment for 0.5-1.5 hours and then absorbing water to burst, removing hemoglobin after centrifugation, washing the lower red blood cell membrane, ultrasonicating for 20-40 minutes, and squeezing out to obtain evenly dispersed red blood cell membrane liposomes.
3. The preparation method according to claim 2, It is characterized in that The hypotonic treatment medium used in the extraction of erythrocyte membranes was (0.25-0.4)×PBS.
4. The preparation method according to any one of claims 1 to 3, It is characterized in that The mass ratio of dihydromyricetin, PLGA and high molecular nonionic surfactant in S1 is 3-5:20-25:25-35.
5. The preparation method according to any one of claims 1 to 3, It is characterized in that The volume ratio of organic solvent to water in S1 is 1-3:5-15.
6. The preparation method according to any one of claims 1 to 3, It is characterized in that The mass volume ratio of dihydromyricetin to organic solvent in S1 is 3-5 mg:1-3 mL.
7. The preparation method according to any one of claims 1 to 3, It is characterized in that The stirring rate in S2 is 600-1200 rpm, and the stirring time is 1-3 h.
8. The preparation method according to any one of claims 1 to 3, It is characterized in that In the step of extracting the red blood cell membrane, the red blood cell membrane is uniformly dispersed by extruding it through a liposome extruder 1-3 times through a 200-400 nm PC membrane.
9. Erythrocyte membrane-encapsulated dihydromyricetin nanoparticles prepared according to the method for preparing erythrocyte membrane-encapsulated dihydromyricetin nanoparticles according to any one of claims 1 to 8.
10. Use of erythrocyte membrane-encapsulated dihydromyricetin nanoparticles prepared according to the preparation method according to any one of claims 1 to 8 in preparing a drug for treating myocardial oxidative damage.
